Arax Advisory Partners’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.6K Buy
1,380
+205
+17% +$1.42K ﹤0.01% 4385
2026
Q2
$7.33K Buy
+1,175
New +$5.07K ﹤0.01% 4470
2026
Q1
– Sell
-15
Closed -$49 – 4141
2025
Q4
$49 Sell
15
-824
-98% -$2.77K ﹤0.01% 3920
2025
Q3
$2.41K Buy
+839
New +$2.14K ﹤0.01% 3074
2025
Q1
– Sell
-4,063
Closed -$22.1K – 2907
2024
Q4
$22.1K Sell
4,063
-1,509
-27% -$9.7K ﹤0.01% 1171
2024
Q3
$46.3K Buy
5,572
+1,332
+31% +$11.5K ﹤0.01% 749
2024
Q2
$30.4K Buy
+4,240
New +$36.6K ﹤0.01% 832
2023
Q1
– Sell
-118
Closed -$1.69K – 1300
2022
Q4
$1.69K Hold
118
– – ﹤0.01% 971
2022
Q3
$3K Hold
118
– – ﹤0.01% 917
2022
Q2
$3K Hold
118
– – ﹤0.01% 902
2022
Q1
$4K Hold
118
– – ﹤0.01% 836
2021
Q4
$5K Hold
118
– – ﹤0.01% 765
2021
Q3
$6K Sell
118
-145
-55% -$7.07K ﹤0.01% 738
2021
Q2
$11K Buy
+263
New +$10.2K ﹤0.01% 653

Other funds holding MRVI

Arax Advisory Partners's MRVI Position: Q3 2026 in Review

Arax Advisory Partners increased its Maravai LifeSciences (MRVI) stake by 17% in Q3 2026, buying an estimated $1.42K and bringing the position to 1,380 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4385.

Arax Advisory Partners first reported a position in MRVI in Q2 2021 and has held it in 14 quarters since. The position peaked at $46.3K in Q3 2024. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

  • Arax Advisory Partners held 1,380 shares of Maravai LifeSciences worth $10.6K as of Q3 2026.
  • Arax Advisory Partners bought 205 Maravai LifeSciences shares in Q3 2026, an estimated $1.42K.
  • Maravai LifeSciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4385 holding.
  • Arax Advisory Partners first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 14 quarters since.
  • Arax Advisory Partners's Maravai LifeSciences position peaked at $46.3K in Q3 2024.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.